Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kemia initiates trial of oral anti-inflammatory
KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. Kemia predicts the drug may be useful for treating inflammatory conditions such
KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. Kemia predicts the drug may be useful for treating inflammatory conditions such
Schering AG will market the product in Europe, and in other countries where Vasovist may receive approval. Millions of people worldwide suffer from various forms of vascular disease.
Proxinium combines a powerful cytotoxic protein payload with the highly precise tumour-targeting characteristics of a monoclonal antibody. A single molecule of the cytotoxic protein payload, Pseudomonas exotoxin, is
ALGRX 3268 is a fast-acting local anesthetic administered into the skin by powder injection and aimed at reducing pain associated with venipuncture procedures such as blood draws and
A research group at the New York University (NYU) School of Medicine have demonstrated that a relatively inexpensive and easy-to-use tool, the electroencephalograph (EEG), can be used to
The orphan drug act guarantees market exclusivity for seven years to the first sponsor that obtains market approval for an orphan-designated product. ZymoGenetics is testing Interleukin 21 (IL-21)
The stem cell niche is a highly specialized microenvironment which surrounds adult stem cells. These niches are key regulators of stem cell activity in mammary tissue. New research
Using an animal model scientists at the Ecole Polytechnique Federale de Lausanne (EPFL) have demonstrated that these holoclones can be used for long-term follicle renewal. The researchers isolated
In addition, the company expects to bring forward into clinical development in 2006 an investigational drug candidate for cystic fibrosis. Vertex’s updated focus on accelerating the clinical development
In January of this year, the company submitted a complete response to a previous approvable letter from the FDA for Zelapar following the successful completion of two safety